Saniona: Selects SAN2355 as a clinical candidate - Redeye

Redeye is positive towards today’s news that Saniona has selected SAN2355 as the first clinical candidate from its KV7 epilepsy program, after announcing in November that it had initiated the candidate selection program. SAN2355 is a subtype-selective activator of Kv7.2/Kv7.3 channels. We hope to learn more about the candidate and the upcoming preclinical program soon.

Länk till analysen i sin helhet: https://www.redeye.se/research/968726/saniona-selects-san2355-as-a-clinical-candidate?utm_source=finwire&utm_medium=RSS